Formulation-dependent Pediatric Physiologically based pharmacokinetic (PPBPK) modeling to aid drug development

Wen Lin, Tycho Heimbach, Handan He
DMPK, Novartis Institutes of Biological Research
June 9, 2016
Outline

- **Introduction**
  - Formulation-dependent Pediatric Physiologically based pharmacokinetic (PPBPK) modeling
  - Common Challenges in PPBPK modeling

- **Applied, Practical formulation-dependent pediatric PBPK Modeling**
  - Case example 1: BCS IV drug
  - Case example 2: BCS II drug

- **Summary/Recommendations**
Workflow for formulation-dependent pediatric PBPK model

With adult human PK data

Confirm

Apply

Learn

Physiochemical, biopharmaceutics, in vitro and in vivo preclinical data

Gut PBPK

Enzyme ontogeny, organ size, blood flows

Verification across pediatric populations

Inform/Predict Future Trials

Adult Clinical Data and Verification

Pediatric Population

Adult Systemic PK, PBPK parameters

Particle size
Dissolution profiles
pKa, solubility
FaSSIF, FeSSIF,
Bile salts enhancement etc
Absorption: formulation dependent

  - Age was not but meal type was
  - GE by aqueous solution: 48 min; GE by solid food: 98 min
- Bile salt concentrations in premature neonates, full-term neonates, infants and children
  - For BCS II and IV compounds, age may impact bile salt enhancement on solubility and in vivo dissolution
  - Food effect in neonates and young infants

Elimination

- In vivo ontogeny profiles for drug metabolizing enzymes: UGTs, Carboxylesterase, etc
- Much less is known about the ontogeny of transporters (BCS III and IV drugs)

Table 5 Pharmacokinetic exposure of artemether, dihydroartemisinin, and lumefantrine: comparison with historical data from older infants and children

<table>
<thead>
<tr>
<th>Time point post-first dose</th>
<th>Current study</th>
<th>Historical data</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ± SD (CV %) [n]</td>
<td>Range</td>
</tr>
<tr>
<td>Artemether concentration (ng/mL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 h</td>
<td>446 ± 321 (72%) [15]</td>
<td>19.7-1210</td>
</tr>
<tr>
<td>2 h</td>
<td>380 ± 262 (68%) [18]</td>
<td>0-933</td>
</tr>
<tr>
<td>Dihydroartemisinin concentration (ng/mL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 h</td>
<td>87.6 ± 58.9 (67%) [15]</td>
<td>7.2-202</td>
</tr>
<tr>
<td>2 h</td>
<td>93.4 ± 67.0 (72%) [18]</td>
<td>0-252</td>
</tr>
<tr>
<td>Lumefantrine concentration (µg/mL)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30 h</td>
<td>No sample taken</td>
<td></td>
</tr>
<tr>
<td>54 h</td>
<td>6.50 ± 3.37 (52%) [17]</td>
<td>0.819-12.5</td>
</tr>
<tr>
<td>66 h</td>
<td>6.04 ± 2.77 (45%) [17]</td>
<td>2.27-12.8</td>
</tr>
<tr>
<td>84 h</td>
<td>3.40 ± 2.28 (67%) [17]</td>
<td>1.16-8.72</td>
</tr>
<tr>
<td>168 h (Day 7)</td>
<td>0.815 ± 0.567 (70%) [16]</td>
<td>0.200-2.39</td>
</tr>
<tr>
<td>336 h</td>
<td>No sample taken</td>
<td></td>
</tr>
</tbody>
</table>

CV, coefficient of variation; h, hour; SD, standard deviation.

Coartem tablets are indicated for treatment of acute, uncomplicated malaria in patients of 5 kg and above.

dispersible tablet (20 mg artemether/120 mg lumefantrine) following a regimen of one dispersible tablet twice daily for 3 days. The consumption of food or drink (mother’s or formula milk) was recommended after dose to enhance lumefantrine absorption.

**Lumefantrine**: Similar exposure in infants < 5 kg (< 3 months) as compared to infants > 5 kg

**Artemether**: 2-3 fold higher exposure in infants < 5 kg (< 3 months) as compared to infants > 5 kg.
Physicochemical and Biopharmaceutical Properties of Lumefantrine

- MW 528.95
- Log P: 8.5 (G+ prediction)
- pKa: 8.3 (G+ prediction)

Solubility – Low

<table>
<thead>
<tr>
<th>Medium</th>
<th>Solubility (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fassif</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Fessif</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>0.1 N HCL</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>water</td>
<td>&lt;0.00005</td>
</tr>
</tbody>
</table>

Permeability – Low

- Caco2 Permeability : Low
- PAMPA Permeability : Low

• Delayed Tmax, long T1/2
• 16 fold food effect observed in HVs; F < 10% under fasting condition

- Lumefantrine can be categorized to pBCS IV (poor permeability, low solubility)
Adult ACAT model can well simulate ~16 fold positive food effect (FDA meal) in HVs

**Formulation parameters included in the ACAT model**

White *et al.* 1999

**Fasting**

**Fed**

- Model correctly predicted ~16 folds higher AUC
- Prediction error for Cmax and AUC < 20%
- Predicted vs. Observed $R^2 = 0.9$

PK parameters determined from IV study

Bile salt enhancement on solubility considered

Particle size, IR dissolution profile incorporated

Patients can’t take Coartem with FDA meal

- Adult patients took minimal food to standard food
- Pediatric patients were recommended to consume some food (e.g. pancake) or drink (eg, breastmilk, broth, or sweetened condensed milk) (Abdulla S, et al 2008)
Soya milk increases Lumefantrine exposure in HVs

Ashley et al, Tropical Medicine and International Health, 2007

- A single Lumefantrine dose, given with 0, 10, 40, 150, 500 mL of soya milk, corresponding to 0, 0.32, 1.28, 4.8 and 16 g fat, respectively.
- Lumefantrine exposure increased up to ~6 fold by 500 mL Soya milk.

Bile salt concentrations in small intestine segments in Lumefantrine ACAT model modified.
- 10 mL Soya milk/ACAT model predicted ~2 fold higher Lumefantrine AUC than fasting condition, comparable to the observed food effect.
10 mL Soya milk/ACAT model can describe the Concentration-Time profile for Lumefantrine in infants with body weight = 5 - 15 kg (> 3 months)

- Japanese female children population > 3 months
- in Gastropluss®
- 10 mL Soya milk/ACAT model
- GI transit time shortened
- Suspension formulation
- Pediatric PBPK model estimated CL
  - Ontogeny of CYP3A4 considered

- ACAT model predicted ~35% F in infants > 5 kg
- Japanese female infant/children population model selected: body weight similar to the tested patients from Africa
- Particle size changed: suspension (smaller particle size) not tablets
Neonates ACAT model could describe Lumefantrine PK profile in Infants (< 3 month) body weight < 5 kg
2 mM bile salts conc. in duodenum

- In neonates, the bile acid concentrations after a meal were about that required for the formation of micellar solutions and solubilization of fat (i.e. 2 mmol/L). Murphy and Singer, 1974
- CL in 1-3 months old infants estimated by PBPK model
- ACAT model predicted F < 10% in infants < 5 kg
- Simcyp pediatric model predicted ~3 fold lower CL in < 3 months old infants than > 3 month old infants
- ~3 folds lower absorption and ~ 3 fold lower CL in < 3 months old infants brought about the comparable Lumefantrine exposure to that in > 3 months old infants
Physicochemical Properties of artemether

- MW 298
- Log P: ~3 (G+ prediction)
- pKa: None (neutral)

**Solubility – Low**
- 0.09 mg/mL (G+ prediction)

**Permeability – high**
- Caco2 Permeability: high
- PAMPA Permeability: high

~2 folds food effect observed in HVs

Artemether can be categorized to pBCS II (poor permeability, low solubility)

At low dose, artemether can be categorized to pBCS I. Clinical dose is 80 mg artemether in adult patients
Simcyp adult PBPK model for artemether can well simulate the observed PK profile in adult patients.

**First-order absorption; minimal PBPK**

- **Artemether PK**: absorbed rapidly, Tmax ~ 2 h; significant first-pass effect
- **2 fold food effect** with FDA meal in HVS: higher artemether Cmax in patients (minimal to standard food taken)
- **PK parameters** derived from the patients PK data
- **Absorption** for 80 mg artemether was estimated 100% by ACAT model in GastroPlus®
Simcyp Pediatric PBPK Model described well the concentration profiles for artemether in infants/children (1 month to 12 yrs): first-order absorption model

- Exposure increased significantly in infants due to immature enzymes (1-3 mon. olds vs. 3-6 mon. olds) and lower body weight (> 5 kg vs. < 5 kg in 1-3 mon. olds)
- Mechanistic PBPK model can reliably simulate observed artemether PK in infant, children and adult

<table>
<thead>
<tr>
<th></th>
<th>Cmax, ng/mL</th>
<th>AUC, ng·h/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 mg artemether</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 to 6 months</td>
<td>453</td>
<td>4303</td>
</tr>
<tr>
<td>(≥5 to &lt;10 kg)</td>
<td>[572 ± 81.3]</td>
<td></td>
</tr>
<tr>
<td>1 to 3 months</td>
<td>714</td>
<td>7246</td>
</tr>
<tr>
<td>(≥5 to &lt;10 kg)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 to 3 months</td>
<td>755</td>
<td>9828</td>
</tr>
<tr>
<td>(&lt;5 kg)</td>
<td>[621 ± 299]</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Cmax, ng/mL</th>
<th>AUC, ng·h/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 to 5 yrs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 5 kg, &lt; 15 kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 -12 yrs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 15 kg, &lt; 25 kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 months to 2 yrs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 5 kg, &lt; 15 kg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Summary/Recommendation

- **BCS II and IV drugs:** food and bile salt may affect drug absorption in neonates and young infants.
  - Mechanism-based absorption mode required: ACAT in GastroPlus® or ADAM in Simcyp®
  - Maximize the food effect PK data in adult population to inform the pediatric absorption model

- **BCS I drug:** first-pass absorption model (ka) from adults to children

- **BCS III drug**
  - Negative food effect observed in adults, it may occur in neonates and young infants
  - Juvenile animal study to inform the absorption prediction in infants and children